Participant flow

Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma · Source last updated 2023-06-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   * Nivolumab will be given every two weeks * The DC/myeloma fusion vaccine/GM-CSF is administered 4 days per cycle Nivolumab: Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells. DC/myeloma fusions/GM-CSF: The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.

   id

   FG000

   title

   Nivolumab+DC/Myeloma Fusions/GM-CSF

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Lack of Efficacy

   2. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Progression Prior to Starting Treatment

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         5

      comment

      Enrolled and had Tumor and Dendritic Cells Collected

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      Initiated Treatment

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         5

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice